These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9834826)

  • 1. Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction.
    Floren LC; Hebert MF; Venook AP; Jordan VC; Cisneros A; Somberg KA
    Ann Oncol; 1998 Oct; 9(10):1123-6. PubMed ID: 9834826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen-induced hepatotoxicity.
    Ahbeddou N; Belbaraka R; Fetohi M; Errihani H
    Indian J Cancer; 2011; 48(3):385. PubMed ID: 21921356
    [No Abstract]   [Full Text] [Related]  

  • 3. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
    Murata Y; Ogawa Y; Saibara T; Nishioka A; Fujiwara Y; Fukumoto M; Inomata T; Enzan H; Onishi S; Yoshida S
    Oncol Rep; 2000; 7(6):1299-304. PubMed ID: 11032933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen-induced submassive hepatic necrosis.
    Storen EC; Hay JE; Kaur J; Zahasky K; Hartmann L
    Cancer J; 2000; 6(2):58-60. PubMed ID: 11069218
    [No Abstract]   [Full Text] [Related]  

  • 5. Tamoxifen-induced transient multifocal hepatic fatty infiltration.
    Cai Q; Bensen M; Greene R; Kirchner J
    Am J Gastroenterol; 2000 Jan; 95(1):277-9. PubMed ID: 10638597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen.
    Hirvikoski PP; Kumpulainen EJ; Johansson RT
    Breast Cancer Res Treat; 1997 Jul; 44(3):269-74. PubMed ID: 9266107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen-induced fatty liver disease in a Caucasian patient.
    Eechoute K; Mathijssen RHJ; van Gelder T
    Breast Cancer Res Treat; 2018 Aug; 171(1):243-244. PubMed ID: 29736740
    [No Abstract]   [Full Text] [Related]  

  • 8. Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen.
    Nemoto Y; Saibara T; Ogawa Y; Zhang T; Xu N; Ono M; Akisawa N; Iwasaki S; Maeda T; Onishi S
    Intern Med; 2002 May; 41(5):345-50. PubMed ID: 12058881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
    Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S
    Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum leptin levels are associated with tamoxifen-induced hepatic steatosis.
    Günel N; Coşkun U; Toruner FB; Sancak B; Yilmaz E; Cengiz O; Elbeg S; Uner A; Ozkan S
    Curr Med Res Opin; 2003; 19(1):47-50. PubMed ID: 12661780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen-induced fatty liver in patients with breast cancer.
    Ogawa Y; Murata Y; Nishioka A; Inomata T; Yoshida S
    Lancet; 1998 Mar; 351(9104):725. PubMed ID: 9504521
    [No Abstract]   [Full Text] [Related]  

  • 12. [Toxic hepatitis associated with tamoxifen use. A case report and literature review].
    Lasso De La Vega MC; Zapater P; Such J; Sola-Vera J; Payá A; Horga JF; Pérez-Mateo M
    Gastroenterol Hepatol; 2002 Apr; 25(4):247-50. PubMed ID: 11975873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Porphyria cutanea tarda induced by tamoxifen.
    Cruz MJ; Alves S; Baudrier T; Azevedo F
    Dermatol Online J; 2010 Sep; 16(9):2. PubMed ID: 20875323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery.
    Hozumi Y; Kawano M; Miyata M
    Endocr J; 1997 Oct; 44(5):745-9. PubMed ID: 9466333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database.
    Helland T; Hagen KB; Haugstøyl ME; Kvaløy JT; Lunde S; Lode K; Lind RA; Gripsrud BH; Jonsdottir K; Gjerde J; Bifulco E; Hustad S; Jonassen J; Aas T; Lende TH; Lien EA; Janssen EAM; Søiland H; Mellgren G
    Breast Cancer Res Treat; 2019 Aug; 177(1):185-195. PubMed ID: 31144152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance.
    Elefsiniotis IS; Pantazis KD; Ilias A; Pallis L; Mariolis A; Glynou I; Kada H; Moulakakis A
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):593-8. PubMed ID: 15167162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced liver injury secondary to tamoxifen.
    Subhaharan D; Murphy G; Commins N; Azer M
    BMJ Case Rep; 2024 Jun; 17(6):. PubMed ID: 38839414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen and depression: drug interactions in breast cancer.
    McMichael KS; Adams K; Breden Crouse EL
    Consult Pharm; 2013 Sep; 28(9):584-91. PubMed ID: 24007891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exacerbation of endometriosis as a result of premenopausal tamoxifen exposure.
    Rose PG; Alvarez B; Maclennan GT
    Am J Obstet Gynecol; 2000 Aug; 183(2):507-8. PubMed ID: 10942499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
    van Nuland M; Vreman RA; Ten Ham RMT; de Vries Schultink AHM; Rosing H; Schellens JHM; Beijnen JH; Hövels AM
    Breast Cancer Res Treat; 2018 Nov; 172(1):143-150. PubMed ID: 30006796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.